• Aethlon Medical disclosed a grant of 42,000 restricted stock units to CFO/CEO James B. Frakes on Oct. 8, 2026.
• The award was issued under the company’s 2020 Equity Incentive Plan, as amended.
• RSUs vest over the one-year period following Oct. 8, 2026, subject to continued service.
• Vesting accelerates to full vesting upon the closing of the proposed merger with North Immunology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007822), on October 13, 2026, and is solely responsible for the information contained therein.